Heska (HSKA) reported Q3 EPS of $0.41, $0.04 better than the analyst estimate of $0.37. Revenue for the quarter came in at $61.5 million versus the consensus estimate of $68.34 million.
2022 Updated Outlook:
This year's challenges in foreign exchange, inflation, interest rates, labor constraints, supply chain, pandemic-era comparisons, pet patient visit trends, delayed regulatory approvals, and the slower-than-expected launch of truRapid™ single use tests and Element AIM® into Europe and other channels have all combined into headwinds to reaching our 2022 Outlook. We are updating our 2022 Updated Outlook to reflect the accumulation of these factors year to date.
- Reported revenue approximately in line with the prior year and up approximately 5% in constant currency.
- North America POC Lab Consumables revenue growth rate of approximately 8%-10% vs prior year.
- International POC Lab Consumables revenue decline of 11%-13% vs prior year on a reported basis, roughly in line with prior year on a constant currency basis.
- Gross margin of 43%-44% and adjusted EBITDA margin at approximately 11%.